Gene alterations at the CDKN2A (p16/MTS1) locus in soft tissue tumors

International Journal of Oncology

Volumn 13, Issue 2, 1998, Pages 325-329

  Schneider Stock, Regine ^a   Walter, Hajo ^a   Haeckel, Carsten ^a   Radig, Kathrin ^a   Rys, Janusz ^b   Roessner, Albert ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

CDKN2A gene; Soft tissue tumors

Indexed keywords

PROTEIN P16;

ARTICLE; CARCINOGENESIS; EXON; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; MISSENSE MUTATION; MUTATION; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; SOFT TISSUE TUMOR; TUMOR SUPPRESSOR GENE;

EID: 0031846285     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.2.325     Document Type: Article

References (33)

1. Cannon-Albright L, Goldgar D, Meyer L, Lewis C, Anderson D, Fountain J, Hegi M, Wiseman R, Petty E, Bale A, Olopade O, Diaz M, Kwiatkowski D, Piepkorn M, Zone J and Skolnick M: Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 258: 1148-1152, 1992.
2. Caldas C, Hahn SA, Da Costa LT, Redston MS, Schutte M, Seymour AB, Weinsten CL, Hruban RH, Yeo CJ and Kern SE: Frequent somatic mutations and homozygous deletions of p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8: 27-32, 1994.
3. Igaki H, Sasaki H, Tachimori Y, Kato H, Watanabe H, Kimura T, Harada Y, Sugimura T and Terada M: Mutation frequency of the p16/CDKN2 gene in primary cancers of the upper digestive tract. Cancer Res 55: 3421-3423, 1995.
4. Williamson MP, Elder PA, Shaw ME, Devlin J and Knowles MA: p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum Mol Genet 4: 1569-1577, 1995.
5. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE and Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440, 1994.
6. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K and Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753-756, 1994.
7. Serrano M, Hannon GJ and Beach D: A new regulatory motif in cell-cycle control causing specific inhibition on cyclin D/CDK4. Nature 366: 704-707, 1993.
8. Hirama T and Koeffler HP: Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 86: 841-854, 1995.
9. INK4A) somatic and germline mutations. Hum Mutat 7: 294-303, 1996.
10. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB and Sidransky D: 5′CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1: 686-692, 1995.
11. Schmidt EE, Ichimura K, Reifenberger G and Collins VP: CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 54: 6321-6324, 1994.
12. Moulton T, Samara G, Chung WY, Yan L, Desai R, Sisti M, Bruce J and Tycko B: MTS1/p16/CDKN2 lesions in primary glioblastomas multiforme. Am J Pathol 146: 613-619, 1995.
13. Li Y, Hoang-Xuan K, Delattre JY, Poisson M, Thomas G and Hamelin R: Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas. Oncogene 11: 597-600, 1995.
14. Schneider-Stock R, Radig K and Roessner A: Loss of heterozygosity on chromosome 9p21 (p16 gene) uncommon in soft-tissue sarcomas. Mol Carcinogen 18: 63-65, 1997.
15. Schneider-Stock R, Radig K, Oda Y, Mellin W, Rys J, Niezabitowski A and Roessner A: P53 gene mutations in soft-tissue sarcomas - correlations with p53 immunohistochemistry and DNA ploidy. J Cancer Res Clin Oncol 123: 211-218, 1997.
16. Sambrook J, Fritsch EF and Maniatis T: Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.
17. Budowle B, Chakraborty R, Giusti AM, Eisenberg AJ and Allen RC: Analysis of the variable number of tandem repeats locus D1S80 by the polymerase chain reaction followed by high resolution polyacrylamide gel electrophoresis. Am J Hum Genet 48: 137-144, 1991.
18. Hayashi K and Yandell DW: How sensitive is PCR-SSCP? Hum Mutat 2: 338-346, 1993.
19. Goldman S and Merril CR: Silver staining of DNA in polyacrylamide gels: linearity and effect of fragment size. Electrophoresis 3: 24-27, 1982.
20. Zhou X, Tarmin L, Yin J, Jiang HY, Suzuki H, Rhyu MG, Abraham JM and Meltzer SJ: The MTS1 gene is frequently mutated in primary human esophageal tumors. Oncogene 9: 3737-3741, 1994.
21. INK4a/CDKN2/MTS1 mutations independent of p53 status in soft tissue sarcomas. J Pathol 184: 14-17, 1998.
22. Pollock PM, Pearson JV and Hayward NK: Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitution. Genes Chromosom Cancer 15: 77-88, 1996.
23. De Vos S, Miller CW, Takeuchi S, Gombart AF, Cho SK and Koeffler HP: Alterations of CDKN2 (p16) in non-small lung cancer. Genes Chromosom Cancer 14: 164-170, 1995.
24. Packenham JP, Taylor JA, Anna CH, White CM and Devereux TR: Homozygous deletions but no sequence mutations in coding regions of p15 or p16 in human primary bladder tumors. Mol Carcinogen 14: 147-151, 1995.
25. Herman JG, Graff JR, Myöhänen S, Nelkin BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826, 1996.
26. He J, Allen JR, Collins VP, Allalunis-Turner MJ, Godbout R, Day RS and James CD: CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res 54: 5804-5807, 1994.
27. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G and Bartek J: Retinoblastoma-protein-dependent cell cycle inhibition by the tumor suppressor p16. Nature 375: 503-506, 1995.
28. Loeb LA: Microsatellite instability: marker of a mutator phenotype in cancer. Cancer Res 54: 5059-5063, 1994.
29. Wooster R, Cleton-Jansen AM, Collins N, Mangion J, Cornelis RS, Cooper CS, Gusterson BA, Ponder BAJ, von Deimling A, Wiestler OD, Cornelisse CJ, Devilee P and Stratton MR: Instability repeats of short tandem repeats (micro-satellites) in human cancers. Nat Genet 6: 152-156, 1994.
30. Yamamoto Y, Virmani A, Wistuba I, McIntire D, Vuitch F, Albores-Saavedra J and Gazdar AF: Loss of heterozygosity and microsatellite alterations in p53 and Rb genes in adenoid cystic carcinoma of salivary glands. Hum Pathol 27: 1204-1210, 1996.
31. Devilee P and Cornelisse CJ: Somatic genetic changes in human breast cancer. Biochim Biophys Acta 1198: 113-130, 1994.
32. Reed JA, Loganzo F, Shea CR, Walker GJ, Flores JF, Glendening JM, Bogdany JK, Shiel MJ, Haluska, FG, Fountain JW and Albino AP: Loss of expression of the p 16/ cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage or tumor progression. Cancer Res 55: 2713-2718, 1995.
33. INK4 in human cancer. Proc Natl Acad Sci USA 91: 11045-11049, 1994.